A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

BACKGROUND: Myelotoxicity during initial cycles of chemotherapy for Hodgkin lymphoma is associated with better outcome, supporting the concept of individualised dosing based on pharmacodynamic end points to optimise results. This study was performed to identify the maximum tolerated dose (MTD) of do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gibb, A, Greystoke, A, Ranson, M, Linton, K, Neeson, S, Hampson, G, Illidge, T, Smith, E, Dive, C, Pettitt, A, Lister, A, Johnson, P, Radford, J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3833204/
https://ncbi.nlm.nih.gov/pubmed/24136151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.605
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados